Respiratory Syncytial Virus Attachment Glycoprotein (RSV G or G) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2021 Update

Pages: 40 Published: November 30, 2021 Report Code: GMDGDHC3024TDB

The respiratory syncytial virus G protein is a protein produced by the respiratory syncytial virus. The Respiratory Syncytial Virus Attachment Glycoprotein drugs in development market research report provides an in-depth analysis of Respiratory Syncytial Virus Attachment Glycoprotein (RSV G or G) targeted pipeline therapeutics. The report provides comprehensive information on the Respiratory Syncytial Virus Attachment Glycoprotein (RSV G or G) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history, and the latest news and press releases.

What are the therapy areas of the Respiratory Syncytial Virus Attachment Glycoprotein pipeline drugs market?

The therapy area of the Respiratory Syncytial Virus Attachment Glycoprotein pipeline drugs market is infectious disease.

What are the indications of the Respiratory Syncytial Virus Attachment Glycoprotein pipeline drugs market?

The indication of the Respiratory Syncytial Virus Attachment Glycoprotein pipeline drugs market is respiratory syncytial virus (RSV) infections.

What are the mechanisms of action of the Respiratory Syncytial Virus Attachment Glycoprotein pipeline drugs market?

The mechanism of action of the Respiratory Syncytial Virus Attachment Glycoprotein pipeline drugs market is Respiratory Syncytial Virus Attachment Glycoprotein Inhibitor.

What are the routes of administration in the Respiratory Syncytial Virus Attachment Glycoprotein pipeline drugs market?

The routes of administration in the Respiratory Syncytial Virus Attachment Glycoprotein pipeline drugs market are intramuscular and nasal.

Respiratory Syncytial Virus Attachment Glycoprotein pipeline drugs market, by routes of administration

Respiratory Syncytial Virus Attachment Glycoprotein pipeline drugs market, by routes of administration

For more routes of administration insights, download a free report sample

What are the molecule types in the Respiratory Syncytial Virus Attachment Glycoprotein pipeline drugs market?

The molecule types in the Respiratory Syncytial Virus Attachment Glycoprotein pipeline drugs market are monoclonal antibody, subunit vaccine, and recombinant vector vaccine.

Respiratory Syncytial Virus Attachment Glycoprotein pipeline drugs market, by molecule types

Respiratory Syncytial Virus Attachment Glycoprotein pipeline drugs market, by molecule types

For more molecule type insights, download a free report sample

Which are the key companies in the Respiratory Syncytial Virus Attachment Glycoprotein pipeline drugs market?

The key companies in the Respiratory Syncytial Virus Attachment Glycoprotein pipeline drugs market are AstraZeneca Plc, Bavarian Nordic A/S, Beijing Advaccine Biotechnology Company Ltd, IDBiologics Inc, Sigmovir Biosystems Inc, and Visterra Inc.

Respiratory Syncytial Virus Attachment Glycoprotein pipeline drugs market, by key companies

Respiratory Syncytial Virus Attachment Glycoprotein pipeline drugs market, by key companies

To know more about key companies, download a free report sample

Market report scope

Therapy Areas Infectious Disease
Indications Respiratory Syncytial Virus (RSV) Infections
Mechanisms of Action Respiratory Syncytial Virus Attachment Glycoprotein Inhibitor
Routes of Administration Intramuscular and Nasal
Molecule Types Monoclonal Antibody, Subunit Vaccine, and Recombinant Vector Vaccine
Key Companies AstraZeneca Plc, Bavarian Nordic A/S, Beijing Advaccine Biotechnology Company Ltd, IDBiologics Inc, Sigmovir Biosystems Inc, and Visterra Inc

This report provides:

  • A snapshot of the global therapeutic landscape of Respiratory Syncytial Virus Attachment Glycoprotein (RSV G or G).
  • Reviews of pipeline therapeutics for Respiratory Syncytial Virus Attachment Glycoprotein (RSV G or G) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • Pipeline products based on several stages of development ranging from pre-registration to discovery and undisclosed stages.
  • Descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • Key players involved in Respiratory Syncytial Virus Attachment Glycoprotein (RSV G or G) therapeutics and enlists all their major and minor projects.
  • Assessment of Respiratory Syncytial Virus Attachment Glycoprotein (RSV G or G) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA), and molecule type.
  • Summaries of all the dormant and discontinued pipeline projects.
  • Reviews of the latest news related to pipeline therapeutics for Respiratory Syncytial Virus Attachment Glycoprotein (RSV G or G).

Reasons to Buy

  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies.
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Identify and understand the targeted therapy areas and indications for Respiratory Syncytial Virus Attachment Glycoprotein (RSV G or G)Identify the use of drugs for target identification and drug repurposing.
  • Identify potential new clients or partners in the target demographic.
  • Develop strategic initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics.
  • Devise corrective measures for pipeline projects by understanding Respiratory Syncytial Virus Attachment Glycoprotein (RSV G or G) development landscape.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

Key Players

  • AstraZeneca Plc

    Bavarian Nordic A/S

    Beijing Advaccine Biotechnology Company Ltd

    IDBiologics Inc

    Sigmovir Biosystems Inc

    Visterra Inc

Table of Contents

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Respiratory Syncytial Virus Attachment Glycoprotein (RSV G or G) – Overview

Respiratory Syncytial Virus Attachment Glycoprotein (RSV G or G) – Therapeutics Development

Products under Development by Stage of Development

Products under Development by Therapy Area

Products under Development by Indication

Products under Development by Companies

Respiratory Syncytial Virus Attachment Glycoprotein (RSV G or G) – Therapeutics Assessment

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Respiratory Syncytial Virus Attachment Glycoprotein (RSV G or G) – Companies Involved in Therapeutics Development

AstraZeneca Plc

Bavarian Nordic A/S

Beijing Advaccine Biotechnology Company Ltd

IDBiologics Inc

Sigmovir Biosystems Inc

Visterra Inc

Respiratory Syncytial Virus Attachment Glycoprotein (RSV G or G) – Drug Profiles

Monoclonal Antibodies to Inhibit RSV-G and F Proteins for RSV Infections – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

respiratory syncytial virus (virus like particle) vaccine – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

respiratory syncytial virus vaccine – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

respiratory syncytial virus vaccine – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

TRL-3D3 – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

VIS-RSV – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Respiratory Syncytial Virus Attachment Glycoprotein (RSV G or G) – Dormant Products

Respiratory Syncytial Virus Attachment Glycoprotein (RSV G or G) – Product Development Milestones

Featured News & Press Releases

Sep 07, 2021: Open Orphan: Positive results from RSV Human Challenge Study

Sep 01, 2021: Bavarian Nordic reports positive results from human challenge trial of its RSV vaccine candidate

Aug 08, 2018: Bavarian Nordic Announces Positive Data from Phase 2 Extension Study of its Universal RSV Vaccine

Mar 06, 2018: Bavarian Nordic Announces Additional Positive Data from a Phase 2 Study of its Universal RSV Vaccine

Nov 09, 2017: Bavarian Nordic Announces Initiation of Phase 2 Booster Study of its Universal RSV Vaccine

Sep 21, 2017: Bavarian Nordic Provides Update on its Universal RSV Vaccine

Jun 27, 2017: Bavarian Nordic Announces Positive Data from Ongoing Phase 2 Study Investigating a Universal RSV Vaccine

Feb 23, 2017: Updated Phase 1 Data Show Bavarian Nordic’s Vaccine Candidate Induces a Broad and Durable Immune Response against RSV

Dec 14, 2016: Bavarian Nordic Announces Completion of Enrollment for Phase 2 Clinical Trial of RSV Vaccine

Oct 18, 2016: Bavarian Nordic Announces Initiation of Phase 2 Clinical Trial of RSV Vaccine

Sep 29, 2016: Bavarian Nordic Announces Presentation Of Phase 1 Data For Its RSV Vaccine At International RSV Symposium

May 23, 2016: Bavarian Nordic Announces Positive Top Line Results from a Phase 1 Trial of a Novel, Broad Spectrum RSV Vaccine in Healthy Adult and Elderly Populations

Aug 18, 2015: Bavarian Nordic Initiates Phase 1 Clinical Trial of MVA-BN in Respiratory Syncitial Virus

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

List of Tables

Number of Products under Development by Stage of Development, 2021

Number of Products under Development by Therapy Areas, 2021

Number of Products under Development by Indication, 2021

Number of Products under Development by Companies, 2021

Products under Development by Companies, 2021

Number of Products by Stage and Mechanism of Actions, 2021

Number of Products by Stage and Route of Administration, 2021

Number of Products by Stage and Molecule Type, 2021

Pipeline by AstraZeneca Plc, 2021

Pipeline by Bavarian Nordic A/S, 2021

Pipeline by Beijing Advaccine Biotechnology Company Ltd, 2021

Pipeline by IDBiologics Inc, 2021

Pipeline by Sigmovir Biosystems Inc, 2021

Pipeline by Visterra Inc, 2021

Dormant Projects, 2021

List of Figures

List of Figures

Number of Products under Development by Stage of Development, 2021

Number of Products by Stage and Mechanism of Actions, 2021

Number of Products by Routes of Administration, 2021

Number of Products by Stage and Routes of Administration, 2021

Number of Products by Molecule Types, 2021

Number of Products by Stage and Molecule Types, 2021

Frequently Asked Questions

$3500

Can be used by individual purchaser only

$10500

Can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

Get in touch to find out about multi-purchase discounts

reportstore@globaldata.com
Tel +44 (0) 20 7947 2960

GDPR + CCPA Compliant

Personal and transaction information are kept safe from unauthorised use.

Recently Viewed Reports

Looking to stay on top of industry & market trends?

Sign up to receive regular alerts for our latest analysis and reports. No matter your industry focus, you can keep your finger on the pulse with our timely updates.